Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

Patients with non-small-cell lung cancer (NSCLC) and brain metastases have previously been excluded from trials of bevacizumab because of suspected risk of CNS hemorrhage. This phase II trial, AVF3752g (PASSPORT), specifically addressed bevacizumab safety (incidence of grade > or = 2 CNS hemorrha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2009-11, Vol.27 (31), p.5255-5261
Hauptverfasser:	SOCINSKI, Mark A, LANGER, Corey J, HUANG, Jane E, KOLB, Margaret M, COMPTON, Peter, LISA WANG, AKERLEY, Wallace
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - secondary Carboplatin - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - secondary Erlotinib Hydrochloride Female Glutamates - therapeutic use Guanine - analogs & derivatives Guanine - therapeutic use Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged Pemetrexed Pneumology Quinazolines - therapeutic use Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!